These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28845861)

  • 1. [Hybrid percutaneous coronary intervention with drug-eluting stent in combination with bioresorbable vascular scaffolds for complex coronary lesions].
    Fineschi M; Carrera A; Pierli C
    G Ital Cardiol (Rome); 2017 Sep; 18(9 Suppl 1):21S-23S. PubMed ID: 28845861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
    Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
    Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions.
    Tanaka A; Jabbour RJ; Mitomo S; Latib A; Colombo A
    JACC Cardiovasc Interv; 2017 Mar; 10(6):539-547. PubMed ID: 28335892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of bioresorbable vascular scaffold Absorb BVS® in patients with stable coronary artery disease: one-year results with special focus on the hybrid bioresorbable vascular scaffolds and drug eluting stents treatment.
    Gil RJ; Bil J; Pawłowski T; Yuldashev N; Kołakowski L; Jańczak J; Jabłoński W; Paliński P
    Kardiol Pol; 2016; 74(7):627-33. PubMed ID: 26779846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further elucidation on "Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI".
    Yew KL
    Int J Cardiol; 2015 Jul; 191():170-1. PubMed ID: 25965626
    [No Abstract]   [Full Text] [Related]  

  • 6. Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents.
    Serruys PW; Katagiri Y; Sotomi Y; Zeng Y; Chevalier B; van der Schaaf RJ; Baumbach A; Smits P; van Mieghem NM; Bartorelli A; Barragan P; Gershlick A; Kornowski R; Macaya C; Ormiston J; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Windecker S; Byrne RA; Räber L; van Geuns RJ; Mintz GS; Onuma Y
    J Am Coll Cardiol; 2017 Jul; 70(1):60-74. PubMed ID: 28662808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI.
    Yew KL
    Int J Cardiol; 2015; 186():74-6. PubMed ID: 25814348
    [No Abstract]   [Full Text] [Related]  

  • 9. Bioresorbable vascular scaffolds: From patient selection to optimal scaffold implantation; tips and tricks to minimize device failure.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):10-20. PubMed ID: 27797460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraindividual Comparison of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Drug-Eluting Metallic Stents.
    Cassese S; Hoppmann P; Kufner S; Byrne RA; Wiebe J; Colleran R; Giacoppo D; Harada Y; Laugwitz KL; Schunkert H; Fusaro M; Kastrati A
    Circ Cardiovasc Interv; 2016 Aug; 9(8):. PubMed ID: 27512088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter regarding "Hybrid ABSORB bioresorbable vascular scaffold and drug eluting stent or hybrid BVS-DES percutaneous coronary intervention: Method and rationale for hybrid overlapping PCI".
    Granata F; Moscarella E; Varricchio A
    Int J Cardiol; 2015 Jul; 190():7-8. PubMed ID: 25912107
    [No Abstract]   [Full Text] [Related]  

  • 13. Bioresorbable vascular scaffolds: design, clinical trials, and current applications.
    Devito F; Zito A; Dachille A; Carbonara R; Giardinelli F; Bulzis G; Navarese EP; Scicchitano P; Gaglione A; Masi F; Ciccone MM
    Coron Artery Dis; 2016 Mar; 27(2):151-8. PubMed ID: 26717005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
    Okamoto N; Ueda H; Yoshimura T; Chamaria S; Bhatheja S; Vengrenyuk Y; Rabiei S; Barrientos Y; Kapur V; Barman N; Sweeny J; Baber U; Mehran R; Sharma SK; Kini AS
    J Invasive Cardiol; 2018 Jul; 30(7):251-255. PubMed ID: 29656280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
    Sorrentino S; Giustino G; Mehran R; Kini AS; Sharma SK; Faggioni M; Farhan S; Vogel B; Indolfi C; Dangas GD
    J Am Coll Cardiol; 2017 Jun; 69(25):3055-3066. PubMed ID: 28412389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transradial experience with bioresorbable vascular scaffolds: A case-matched study with metallic drug-eluting stents.
    Maes F; Costerousse O; Cieza T; Henry M; Déry JP; Barbeau G; Delarochellière R; Paradis JM; Larose E; Nguyen CM; Pirlet C; Mongrain R; Bertrand OF
    Cardiovasc Revasc Med; 2018 Sep; 19(6):700-704. PubMed ID: 29398632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Planned use of GP IIb/IIIa inhibitors is safe and effective during implantation of the Absorb Bioresorbable Vascular Scaffold.
    Jessup DB; Grove MM; Marks S; Kirby A
    Cardiovasc Revasc Med; 2018 Dec; 19(8):956-959. PubMed ID: 30097189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioresorbable Vascular Scaffold: A Focused Review on Development and Preclinical Studies].
    Ke L; Huang Y; Liu L; Duan X; Feng X; Wang C
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Feb; 42(2):115-118. PubMed ID: 29845812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.